Menu
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
?12.40

?12.40

 
WKN: A2JPEV / Symbol: VRCA / Name: Verrica Pharmaceuticals / Stock / Small Cap /
Latest predictions
€10.31
26.05.26
-
buy
07.01.26
-
buy
€14.48
18.12.25
-
buy
Your prediction

Verrica Pharmaceuticals Stock

Currently there is a rather positive sentiment for Verrica Pharmaceuticals with 3 Buy predictions and 0 Sell predictions.
Based on the current price of 0.58 € the target price of 12 € shows a potential of 1965.4% for Verrica Pharmaceuticals which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Verrica Pharmaceuticals stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Verrica Pharmaceuticals in the next few years

Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Prediction Buy
Perf. (%) -
Target price 10.314
Change
Ends at 26.05.27

Verrica Pharmaceuticals (VRCA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for VRCA provided by MarketBeat
Show more

Verrica Pharmaceuticals (NASDAQ:VRCA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Ratings data for VRCA provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -
Target price 14.482
Change
Ends at 18.12.26

Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.
Ratings data for VRCA provided by MarketBeat
Show more